Rapport CEO Sells 10,916 Shares in 10b5-1 Plan

Rapport Therapeutics Chief Executive Officer Abraham Ceesay reported open-market sales of a total of 10,916 shares of common stock on February 18 under pre-arranged Rule 10b5-1 trading plans.

Rhea-AI Filing Summary

Rapport Therapeutics Chief Executive Officer Abraham Ceesay reported open-market sales of a total of 10,916 shares of common stock on February 18 under pre-arranged Rule 10b5-1 trading plans. He sold 5,833 shares held directly, at weighted average prices of $29.0516 and $29.7983 per share. An additional 5,083 shares were sold by The Dorothy Ceesay Irrevocable Trust, also at weighted average prices around $29 per share, with Ceesay disclaiming beneficial ownership except for any pecuniary interest. After these transactions, he holds 556,247 shares directly, while trusts associated with him hold 20,729 and 81,729 shares, respectively.

Insider Trade Summary

Net Seller: 10,916 shares

Net Sell 5 txns

Insider Ceesay Abraham

Role Chief Executive Officer

Sold 10,916 shs ($320K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,552	$29.0516	$103K
Sale	Common Stock	2,281	$29.7983	$68K
Sale	Common Stock	2,983	$29.0443	$87K
Sale	Common Stock	2,100	$29.7965	$63K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 556,247 shares (Direct); Common Stock — 20,729 shares (Indirect, By Dorothy Ceesay Irrevocable Trust); Common Stock — 81,729 shares (Indirect, By Ceesay Family Irrevocable Trust)

Footnotes (7)

1. F1. These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.56 to $30.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
4. F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
5. F5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.52 to $30.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
6. F6. Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
7. F7. Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rapport Therapeutics (RAPP) CEO Abraham Ceesay report?

CEO Abraham Ceesay reported selling 10,916 shares of Rapport Therapeutics common stock. This included 5,833 shares held directly and 5,083 shares sold by a related irrevocable trust, all executed as open-market sales at weighted average prices around $29 per share.

Were the Rapport Therapeutics (RAPP) CEO share sales under a Rule 10b5-1 plan?

Yes, the reported sales were executed under Rule 10b5-1 trading plans adopted on December 12, 2024. Such plans allow pre-scheduled trades, helping insiders diversify holdings while reducing concerns that sales reflect non-public information or short-term views.

How many Rapport Therapeutics (RAPP) shares does CEO Abraham Ceesay hold after the Form 4?

After the reported transactions, Abraham Ceesay holds 556,247 Rapport Therapeutics shares directly. In addition, trusts associated with him hold 20,729 shares in The Dorothy Ceesay Irrevocable Trust and 81,729 shares in The Ceesay Family Irrevocable Trust, subject to his beneficial-ownership disclaimers.

What role did family trusts play in the Rapport Therapeutics (RAPP) Form 4 transactions?

Part of the reported selling activity occurred in The Dorothy Ceesay Irrevocable Trust, which sold 5,083 shares. Shares are also held by The Ceesay Family Irrevocable Trust. Ceesay disclaims beneficial ownership of these trust-held shares except for any pecuniary interest he may have.

At what prices were the Rapport Therapeutics (RAPP) insider sales executed?

The Form 4 lists weighted average sale prices near $29 per share. Individual trades occurred in ranges from $28.51 to $30.09, reflecting multiple open-market executions, with the insider offering to provide detailed price breakdowns upon request to shareholders or regulators.

Does the Rapport Therapeutics (RAPP) Form 4 indicate whether sales were open-market transactions?

Yes, the transactions are described as open-market sales of common stock. They were executed at various prices within disclosed ranges, and each reported price is a weighted average across multiple individual trades completed on February 18 as part of the 10b5-1 plans.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 07:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ceesay Abraham

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		S(1)		3,552	D	$29.0516(2)	558,528	D
Common Stock	02/18/2026		S(1)		2,281	D	$29.7983(3)	556,247	D
Common Stock	02/18/2026		S(1)		2,983	D	$29.0443(4)	22,829	I	By Dorothy Ceesay Irrevocable Trust(6)
Common Stock	02/18/2026		S(1)		2,100	D	$29.7965(5)	20,729	I	By Dorothy Ceesay Irrevocable Trust(6)
Common Stock								81,729	I	By Ceesay Family Irrevocable Trust(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.56 to $30.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.52 to $30.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

6. Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

7. Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

	/s/ Troy Ignelzi, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.